TABLE 3.

Multivariable regression analyses for all included trials, and trials with and without stated funding from the industry*.

	All trials (N = 250)		Industry-funded trials (N = 106)		Non-industry funded trials (N = 119)
	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	p
Drug trial (vs. non-drug trial)	0.53 (0.29 – 0.97)	0.04	0.49 (0.18 – 1.27)	0.15	0.50 (0.20 – 1.20)	0.12
Multicentre (vs. single center)	0.39 (0.18 – 0.80)	0.01	0.13 (0.02 – 0.61)	0.02	0.80 (0.32 – 2.00)	0.64
Sample size (>500 vs. smaller)	0.67 (0.34 – 1.31)	0.24	0.60 (0.23 – 1.56)	0.29	1.72 (0.52 – 6.86)	0.40
Data Monitoring Committee (yes vs. no)	0.59 (0.32 – 1.09)	0.09	0.36 (0.13 – 0.96)	0.045	0.91 (0.37 – 2.27)	0.84
Primary outcome statistically significant (vs. not)	0.92 (0.48 – 1.74)	0.80	0.52 (0.81 – 1.11)	0.49	1.36 (0.54 – 3.38)	0.51
Trial registration reported (vs. not reported)	0.06 (0.003 – 0.31)	<0.01	0.19 (0.01 – 1.28)	0.15	1.13 (0.01 – 0.75)	0.06

*Funding was not reported in N = 25 studies.